Donghai Jiang

814 total citations
24 papers, 658 citations indexed

About

Donghai Jiang is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Donghai Jiang has authored 24 papers receiving a total of 658 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Donghai Jiang's work include Drug Transport and Resistance Mechanisms (5 papers), Estrogen and related hormone effects (4 papers) and Cancer-related molecular mechanisms research (4 papers). Donghai Jiang is often cited by papers focused on Drug Transport and Resistance Mechanisms (5 papers), Estrogen and related hormone effects (4 papers) and Cancer-related molecular mechanisms research (4 papers). Donghai Jiang collaborates with scholars based in China, Madagascar and United States. Donghai Jiang's co-authors include Lin Zhou, Weimin Fan, Danni Chen, Liang Xu, Haiyang Xie, Meihua Sui, Shusen Zheng, Bisha Ding, Weimin Fan and Xiao Xu and has published in prestigious journals such as Cancer Research, Cell Death and Differentiation and Cancer Letters.

In The Last Decade

Donghai Jiang

24 papers receiving 654 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donghai Jiang China 13 407 260 144 109 89 24 658
Chong Du China 18 569 1.4× 323 1.2× 194 1.3× 104 1.0× 70 0.8× 41 898
Jiuxia Pang United States 17 714 1.8× 220 0.8× 160 1.1× 92 0.8× 58 0.7× 20 970
Zhiwang Song China 15 473 1.2× 303 1.2× 226 1.6× 69 0.6× 58 0.7× 23 762
Yusha Xiao China 14 489 1.2× 332 1.3× 91 0.6× 86 0.8× 124 1.4× 24 838
Dimas Carolina Belisario Italy 16 401 1.0× 247 0.9× 252 1.8× 109 1.0× 69 0.8× 19 868
Allen Zhang United States 10 397 1.0× 141 0.5× 133 0.9× 77 0.7× 76 0.9× 16 565
Junping Ao China 15 434 1.1× 194 0.7× 112 0.8× 86 0.8× 43 0.5× 24 687
Chunyu Hou China 12 359 0.9× 258 1.0× 68 0.5× 98 0.9× 128 1.4× 37 662
Bikash Chandra Jena India 13 451 1.1× 236 0.9× 144 1.0× 45 0.4× 46 0.5× 24 667
Chun-Ying Qu China 14 271 0.7× 152 0.6× 104 0.7× 45 0.4× 97 1.1× 25 563

Countries citing papers authored by Donghai Jiang

Since Specialization
Citations

This map shows the geographic impact of Donghai Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donghai Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donghai Jiang more than expected).

Fields of papers citing papers by Donghai Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donghai Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donghai Jiang. The network helps show where Donghai Jiang may publish in the future.

Co-authorship network of co-authors of Donghai Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Donghai Jiang. A scholar is included among the top collaborators of Donghai Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donghai Jiang. Donghai Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Hao, et al.. (2025). Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer. Phytomedicine. 146. 157117–157117. 2 indexed citations
2.
Zhang, Liang, Wei Chen, Wei Zhang, et al.. (2023). DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy. International Journal of Biological Sciences. 19(11). 3412–3427. 7 indexed citations
3.
Owusu-Ansah, Kwabena Gyabaah, et al.. (2022). Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. Heliyon. 8(12). e12064–e12064. 7 indexed citations
4.
Zhou, Wei, Weiyang Lou, Junru Chen, et al.. (2021). AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest. OncoTargets and Therapy. Volume 14. 1049–1059. 3 indexed citations
5.
Chen, Ronggao, Qiyang Cheng, Kwabena Gyabaah Owusu-Ansah, et al.. (2020). NKILA, a prognostic indicator, inhibits tumor metastasis by suppressing NF-κB/Slug mediated epithelial-mesenchymal transition in hepatocellular carcinoma. International Journal of Biological Sciences. 16(3). 495–503. 30 indexed citations
6.
Zhang, Yanpeng, Ronggao Chen, Kwabena Gyabaah Owusu-Ansah, et al.. (2020). Y-320, a novel immune-modulator, sensitizes multidrug-resistant tumors to chemotherapy.. PubMed. 12(2). 551–562. 9 indexed citations
7.
Lou, Weiyang, Jin‐Xing Liu, Bisha Ding, et al.. (2019). Identification of potential miRNA–mRNA regulatory network contributing to pathogenesis of HBV-related HCC. Journal of Translational Medicine. 17(1). 7–7. 77 indexed citations
8.
Owusu-Ansah, Kwabena Gyabaah, Guangyuan Song, Ronggao Chen, et al.. (2019). COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer. International Journal of Oncology. 55(2). 391–404. 50 indexed citations
9.
Chen, Ronggao, Yiting Qiao, Wendi Hu, et al.. (2019). LY2228820 induces synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein in multidrug resistant cancer cells.. PubMed. 9(10). 2216–2232. 3 indexed citations
10.
Lou, Weiyang, Jing Chen, Bisha Ding, et al.. (2018). Identification of invasion-metastasis-associated microRNAs in hepatocellular carcinoma based on bioinformatic analysis and experimental validation. Journal of Translational Medicine. 16(1). 266–266. 70 indexed citations
11.
Chen, Ronggao, Qiyang Cheng, Kwabena Gyabaah Owusu-Ansah, et al.. (2018). Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma.. PubMed. 8(7). 1297–1306. 17 indexed citations
12.
Wang, Hangxiang, Zhongjie Lu, Lijiang Wang, et al.. (2017). New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity. Cancer Research. 77(24). 6963–6974. 133 indexed citations
13.
Shen, Jiaying, Chengyong Du, Danni Chen, et al.. (2017). A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance. Cell Death and Differentiation. 25(2). 406–420. 78 indexed citations
14.
Huang, Yu‐An, Donghai Jiang, Meihua Sui, Xiaojia Wang, & Weimin Fan. (2016). Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression. Oncology Reports. 37(2). 705–712. 20 indexed citations
15.
Xu, Mingjie, Donghai Jiang, Jiaying Shen, Huilin Zheng, & Weimin Fan. (2016). Distinct characterization of two vinorelbine-resistant breast cancer cell lines developed by different strategies. Oncology Reports. 35(4). 2355–2363. 5 indexed citations
16.
Xu, Liang, et al.. (2015). Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells. Cancer Biology & Therapy. 16(12). 1794–1801. 4 indexed citations
17.
Jiang, Donghai, Yuan Huang, Mingjie Xu, et al.. (2014). Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy. Cancer Letters. 346(2). 292–299. 15 indexed citations
18.
Jiang, Donghai, et al.. (2013). Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells. Cancer Letters. 335(2). 404–411. 37 indexed citations
19.
Jin, Na, et al.. (2011). The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus. International Immunopharmacology. 11(9). 1319–1326. 33 indexed citations
20.
Sui, Meihua, et al.. (2009). Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor α to vinblastine and vinorelbine. Breast Cancer Research and Treatment. 121(2). 335–345. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chong Du Breakdown of academic impact, for papers by Jiuxia Pang Breakdown of academic impact, for papers by Zhiwang Song Breakdown of academic impact, for papers by Yusha Xiao Breakdown of academic impact, for papers by Dimas Carolina Belisario Breakdown of academic impact, for papers by Allen Zhang Breakdown of academic impact, for papers by Junping Ao Breakdown of academic impact, for papers by Chunyu Hou Breakdown of academic impact, for papers by Bikash Chandra Jena Breakdown of academic impact, for papers by Chun-Ying Qu
Rankless by CCL
2026